These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 29514108)

  • 1. Low-level clonal FGFR2 amplification defines a unique molecular subtype of intrahepatic cholangiocarcinoma in a Chinese population.
    Pu XH; Ye Q; Yang J; Wu HY; Ding XW; Shi J; Mao L; Fan XS; Chen J; Qiu YD; Huang Q
    Hum Pathol; 2018 Jun; 76():100-109. PubMed ID: 29514108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
    Graham RP; Barr Fritcher EG; Pestova E; Schulz J; Sitailo LA; Vasmatzis G; Murphy SJ; McWilliams RR; Hart SN; Halling KC; Roberts LR; Gores GJ; Couch FJ; Zhang L; Borad MJ; Kipp BR
    Hum Pathol; 2014 Aug; 45(8):1630-8. PubMed ID: 24837095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-MET in intrahepatic cholangiocarcinoma: High-Frequency amplification predicts protein expression and a unique molecular subtype.
    Pu XH; Yue S; Wu HY; Yang J; Fan XS; Fu Y; Ye Q; Chen J
    Pathol Res Pract; 2020 Apr; 216(4):152857. PubMed ID: 32089411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target molecular treatment markers in Intrahepatic Cholangiocarcinoma based on Chinese population.
    Pu X; Zhu L; Li F; Zheng J; Wu H; Fu Y; Chen J; Qi L
    Pathol Res Pract; 2020 Sep; 216(9):153116. PubMed ID: 32825971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas.
    Pu X; Ye Q; Cai J; Yang X; Fu Y; Fan X; Wu H; Chen J; Qiu Y; Yue S
    Cell Death Dis; 2021 Mar; 12(3):256. PubMed ID: 33692336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma.
    Li F; Peiris MN; Donoghue DJ
    Cytokine Growth Factor Rev; 2020 Apr; 52():56-67. PubMed ID: 31899106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma.
    Tsujie M; Iwai T; Kubo S; Ura T; Hatano E; Sakai D; Takeda Y; Kaibori M; Kobayashi T; Katanuma A; Katayose Y; Fukase K
    Jpn J Clin Oncol; 2021 May; 51(6):911-917. PubMed ID: 33822966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of fibroblast growth factor receptor 2 (FGFR2) in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma: clinicopathological study.
    Sasaki M; Sato Y; Nakanuma Y
    Virchows Arch; 2024 Jun; 484(6):915-923. PubMed ID: 38532197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
    Javle M; Lowery M; Shroff RT; Weiss KH; Springfeld C; Borad MJ; Ramanathan RK; Goyal L; Sadeghi S; Macarulla T; El-Khoueiry A; Kelley RK; Borbath I; Choo SP; Oh DY; Philip PA; Chen LT; Reungwetwattana T; Van Cutsem E; Yeh KH; Ciombor K; Finn RS; Patel A; Sen S; Porter D; Isaacs R; Zhu AX; Abou-Alfa GK; Bekaii-Saab T
    J Clin Oncol; 2018 Jan; 36(3):276-282. PubMed ID: 29182496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphoepithelioma-like Intrahepatic Cholangiocarcinoma Is a Distinct Entity With Frequent pTERT/TP53 Mutations and Comprises 2 Subgroups Based on Epstein-Barr Virus Infection.
    Tsai JH; Liau JY; Lee CH; Jeng YM
    Am J Surg Pathol; 2021 Oct; 45(10):1409-1418. PubMed ID: 33859071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.
    Borad MJ; Gores GJ; Roberts LR
    Curr Opin Gastroenterol; 2015 May; 31(3):264-8. PubMed ID: 25763789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma.
    Sia D; Losic B; Moeini A; Cabellos L; Hao K; Revill K; Bonal D; Miltiadous O; Zhang Z; Hoshida Y; Cornella H; Castillo-Martin M; Pinyol R; Kasai Y; Roayaie S; Thung SN; Fuster J; Schwartz ME; Waxman S; Cordon-Cardo C; Schadt E; Mazzaferro V; Llovet JM
    Nat Commun; 2015 Jan; 6():6087. PubMed ID: 25608663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic role of BAP-1 and PBRM-1 expression in intrahepatic cholangiocarcinoma.
    Sarcognato S; Gringeri E; Fassan M; Di Giunta M; Maffeis V; Guzzardo V; Cillo U; Guido M
    Virchows Arch; 2019 Jan; 474(1):29-37. PubMed ID: 30377796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DLEC1 methylation is associated with a better clinical outcome in patients with intrahepatic cholangiocarcinoma of the small duct subtype.
    Kim Y; Lee K; Jeong S; Wen X; Cho NY; Kang GH
    Virchows Arch; 2019 Jul; 475(1):49-58. PubMed ID: 30610381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma.
    Mahipal A; Tella SH; Kommalapati A; Anaya D; Kim R
    Cancer Treat Rev; 2019 Aug; 78():1-7. PubMed ID: 31255945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival.
    Ahn S; Lee J; Hong M; Kim ST; Park SH; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Jung SH; Kang WK; Kim KM
    Mod Pathol; 2016 Sep; 29(9):1095-103. PubMed ID: 27230412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gatekeeper Mutations and Intratumoral Heterogeneity in
    Smyth EC; Babina IS; Turner NC
    Cancer Discov; 2017 Mar; 7(3):248-249. PubMed ID: 28264865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological characteristics and prognosis of combined hepatocellular cholangiocarcinoma.
    Li Y; He D; Lu ZJ; Gu XF; Liu XY; Chen M; Tu YX; Zhou Y; Owen G; Zhang X; Jiang D
    BMC Cancer; 2024 Oct; 24(1):1232. PubMed ID: 39375615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDM2 Amplification in Intrahepatic Cholangiocarcinomas: Its Relationship With Large-Duct Type Morphology and Uncommon KRAS Mutations.
    Kim SJ; Akita M; Sung YN; Fujikura K; Lee JH; Hwang S; Yu E; Otani K; Hong SM; Zen Y
    Am J Surg Pathol; 2018 Apr; 42(4):512-521. PubMed ID: 29309301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyclonal Secondary
    Goyal L; Saha SK; Liu LY; Siravegna G; Leshchiner I; Ahronian LG; Lennerz JK; Vu P; Deshpande V; Kambadakone A; Mussolin B; Reyes S; Henderson L; Sun JE; Van Seventer EE; Gurski JM; Baltschukat S; Schacher-Engstler B; Barys L; Stamm C; Furet P; Ryan DP; Stone JR; Iafrate AJ; Getz G; Porta DG; Tiedt R; Bardelli A; Juric D; Corcoran RB; Bardeesy N; Zhu AX
    Cancer Discov; 2017 Mar; 7(3):252-263. PubMed ID: 28034880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.